Talaris Therapeutics Inc (TALS) Stock: Do Analysts Think You Should Accumulate?

Wednesday, June 28, 2023 01:52 PM | InvestorsObserver Analysts

Mentioned in this article

Talaris Therapeutics Inc (TALS) Stock: Do Analysts Think You Should Accumulate?

InvestorsObserver is giving Talaris Therapeutics Inc (TALS) an Analyst Rating Rank of 5, meaning TALS is ranked higher by analysts than 5% of stocks. The average price target for TALS is $3 and analyst’s rate the stock as a Hold.

Wall Street analysts are rating TALS a Hold today. Find out what this means to you and get the rest of the rankings on TALS!

See Full TALS Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Talaris Therapeutics Inc Stock Today?

Talaris Therapeutics Inc (TALS) stock has risen 5.61% while the S&P 500 has fallen -0.23% as of 1:52 PM on Wednesday, Jun 28. TALS is higher by $0.17 from the previous closing price of $3.03 on volume of 582,401 shares. Over the past year the S&P 500 is up 14.31% while TALS has fallen -54.55%. TALS lost -$1.88 per share the over the last 12 months. Click Here to get the full Stock Report for Talaris Therapeutics Inc stock.